What We're Reading: Page 104
Industry reads hand-picked by our editors
Sep 02, 2022
-
Bloomberg
Drug Recalls for Nitrosamines Could Cost Big Pharma Millions
-
FierceBiotech
Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
-
BioCentury
Inflation act has slashed value of small molecules: Lilly’s Ricks
-
Endpoints News
Pfizer reshuffles top leadership to hone commercial strategy, leaving room for new rare disease chief
Sep 01, 2022
Aug 31, 2022
-
NPR
Life expectancy in the U.S. fell for a second year in a row, driven by COVID-19
-
FiercePharma
Novartis hit with Entresto patent suit amid generics fight
-
Science
Philanthropist donates $172 million to speed up drug development for the next pandemic
-
MarketWatch
Sanofi Hemophilia Drug Granted Priority Review by U.S. FDA
Aug 30, 2022
-
Science
Scientists question Moderna invention claim in COVID-19 vaccine dispute
-
The Boston Globe
Despite industry-wide stock slump, Mass biotech startups raised $5.1 billion in the first half of 2022
-
BioCentury
It’s not a fraternity anymore
-
Endpoints News
China’s DNA giant confronts skepticism in US expansion bid
Aug 29, 2022
-
STAT
For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career
-
The New York Times
How to Get Heart Patients to Take Their Pills? Give Them Just One.
-
Chemical & Engineering News
Drug developers look to lysine on disease-linked proteins
-
The Wall Street Journal
Latest Covid Boosters Are Set to Roll Out Before Human Testing Is Completed
Previous
